RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:52416

Mantle cell lymphoma

medium confidenceDisorder

Also known as: LCM · MCL · Mantle zone lymphoma

Publications

22,712

97.9th percentile

Trials

716

Interventional, condition-specific

Researchers

1,456

Distinct authors in sample

Gene link

—

Readiness

4/6

Stages with a signal

Clinical definition (Orphanet)

Mantle cell lymphoma is a rare form of malignant non-Hodgkin lymphoma affecting B lymphocytes in the lymph nodes in a region called the ``mantle zone''.

How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (3)

classical mantle cell lymphoma · mantle cell lymphoma · mantle zone lymphoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

4/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    22,712 matched papers (14,247 in last 10 years) Source

  3. Phenotype characterisedPresent

    9 HPO annotations (e.g. Weight loss; Anorexia; Lymphadenopathy) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationPresent

    12 FDA · 8 EMA designations (8 FDA orphan-indication approvals) — e.g. Orelabrutinib Source

  6. Interventional trialPresent

    716 matched on ClinicalTrials.gov (114 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

9

Associated phenotypes · MONDO:0018876

  • Weight loss
  • Anorexia
  • Lymphadenopathy
  • Abnormal bone marrow cell morphology
  • Abnormality of the gastrointestinal tract

Showing 5 of 9 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

28

Designations · 8 with FDA orphan-indication approval

  • FDA OrelabrutinibMantle cell lymphoma · 2020-12-30 · Not FDA Approved for Orphan Indication
  • FDA cirmtuzumabMantle cell lymphoma · 2020-06-22 · Not FDA Approved for Orphan Indication
  • FDA lisocabtagene maraleucelMantle cell lymphoma · 2020-04-01 · Not FDA Approved for Orphan Indication
  • FDA parsaclisibMantle cell lymphoma · 2019-06-12 · Not FDA Approved for Orphan Indication
  • FDA venetoclaxMantle cell lymphoma · 2017-08-31 · Not FDA Approved for Orphan Indication
  • FDA Humanized monoclonal immunoglobulin G1 antibody directed against human CD19 conjugated to SG3199 through a protease cleavable valine-alanine linkerMantle cell lymphoma · 2017-06-08 · Not FDA Approved for Orphan Indication
  • FDA daratumumabMantle cell lymphoma · 2015-08-20 · Not FDA Approved for Orphan Indication
  • FDA dasiprotimut-TMantle cell lymphoma · 2010-06-17 · Not FDA Approved for Orphan Indication

Sources: FDA OOPD · EMA orphan designations

Open Targets candidates

191

Drugs / clinical candidates · MONDO_0018876

CTD chemicals (MyDisease.info)

14 associated chemicals · 287 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.

  • ABT-737 · therapeutic
  • Amifostine · therapeutic
  • Arsenic Trioxide · therapeutic
  • Bendamustine Hydrochloride · therapeutic
  • Bortezomib · therapeutic
  • CHOP protocol · therapeutic
  • Cytarabine · therapeutic
  • fludarabine · therapeutic
  • GSK3235025 · therapeutic
  • ibrutinib · therapeutic
  • Mitoxantrone · therapeutic
  • Paclitaxel · therapeutic

Pathways: Purine metabolism; Inositol phosphate metabolism; Thiamine metabolism; Metabolic pathways; EGFR tyrosine kinase inhibitor resistance; Endocrine resistance; Platinum drug resistance; RNA transport

MyDisease.info · MONDO:0018876

Literature

Is anyone studying this?

22,712

22,712 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

22,712 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

14,247 in the last 10 years · medium confidence · 97.9th percentile (publications denominator)

Phrase hits: 22,707 · MeSH hits: 62

Open Europe PMC search

Who's working on it?

1,456

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Wang Y9 papers · 2026

    Department of Pharmacology, Liaoning Key Lab of Targeting Drugs for Hematological Malignancies, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China.

    Papers in Europe PMC
  2. 02
    Ladetto M8 papers · 2026

    Division of Hematology Antonio e Biagio e Cesare Arrigo Hospital Alessandria Italy.

    Papers in Europe PMC
  3. 03
    Wang M8 papers · 2026

    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. miwang@mdanderson.org.

    Papers in Europe PMC
  4. 04
    Eyre TA7 papers · 2026

    Haematology and Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, UK.

    Papers in Europe PMC
  5. 05
    Zhang W7 papers · 2026

    Department of Hematology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

    Papers in Europe PMC
  6. 06
    Zhang Y7 papers · 2026

    Department of Life Sciences, Bengbu Medical University, Bengbu, Anhui, China.

    Papers in Europe PMC
  7. 07
    Dreyling M6 papers · 2026

    Department of Medicine III LMU Hospital Munich Germany.

    Papers in Europe PMC
  8. 08
    Jing H6 papers · 2026

    Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China.

    Papers in Europe PMC
  9. 09
    Liu Y6 papers · 2026

    Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China.

    Papers in Europe PMC
  10. 10
    Wang J6 papers · 2026

    Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

716

interventional trials for this specific condition

716 interventional trials matched this specific condition name; 114 currently recruiting in our sample.

Data as of 11 September 2026

716 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 99.8th percentile).

medium confidence · 99.8th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

716 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

48 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 71 · after dedupe 71 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 71 · dropped 0 · fetched 2026-07-29

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (71)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Mantle cell lymphoma — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Mantle cell lymphoma" OR "Mantle zone lymphoma" OR "classical mantle cell lymphoma"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Lymphoma, Mantle-Cell

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Mantle cell lymphoma" OR "Mantle zone lymphoma" OR "classical mantle cell lymphoma" OR "Lymphoma, Mantle-Cell"

Interventional trials matched via: both, phrase, mesh (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 716 interventional · 48 observational · 4 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: LCM; MCL

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 2 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T00:48:35.097Z